Literature DB >> 28290631

Acute Coronary Syndrome: Current Treatment.

Timothy L Switaj1, Scott R Christensen2, Dean M Brewer3.   

Abstract

Acute coronary syndrome continues to be a significant cause of morbidity and mortality in the United States. Family physicians need to identify and mitigate risk factors early, as well as recognize and respond to acute coronary syndrome events quickly in any clinical setting. Diagnosis can be made based on patient history, symptoms, electrocardiography findings, and cardiac biomarkers, which delineate between ST elevation myocardial infarction and non-ST elevation acute coronary syndrome. Rapid reperfusion with primary percutaneous coronary intervention is the goal with either clinical presentation. Coupled with appropriate medical management, percutaneous coronary intervention can improve short- and long-term outcomes following myocardial infarction. If percutaneous coronary intervention cannot be performed rapidly, patients with ST elevation myocardial infarction can be treated with fibrinolytic therapy. Fibrinolysis is not recommended in patients with non-ST elevation acute coronary syndrome; therefore, these patients should be treated with medical management if they are at low risk of coronary events or if percutaneous coronary intervention cannot be performed. Post-myocardial infarction care should be closely coordinated with the patient's cardiologist and based on a comprehensive secondary prevention strategy to prevent recurrence, morbidity, and mortality.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28290631

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  7 in total

Review 1.  Sweet dreams: How mini-invasive surgery tackles obstructive sleep apnea.

Authors:  Sophia Julia Häfner
Journal:  Biomed J       Date:  2019-05-20       Impact factor: 4.910

Review 2.  Fondaparinux: A cornerstone drug in acute coronary syndromes.

Authors:  Mohammed Yunus Khan; Chandrashekhar K Ponde; Viveka Kumar; Kumar Gaurav
Journal:  World J Cardiol       Date:  2022-01-26

3.  Identification of key molecular markers of acute coronary syndrome using peripheral blood transcriptome sequencing analysis and mRNA-lncRNA co-expression network construction.

Authors:  Ming Shen; Rui Gong; Haibin Li; Zhihui Yang; Yunpeng Wang; Dandan Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Up to 15-Year Survival of Men and Women after Percutaneous Coronary Intervention Paid by the Brazilian Public Healthcare System in the State of Rio de Janeiro, 1999-2010.

Authors:  Christina Grüne de Souza E Silva; Carlos Henrique Klein; Paulo Henrique Godoy; Lucia Helena Alvares Salis; Nelson Albuquerque de Souza E Silva
Journal:  Arq Bras Cardiol       Date:  2018-10-18       Impact factor: 2.000

5.  The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.

Authors:  Zhaowei Zhang; Mingxiao Chen; Long Zhang; Qiang Zhao
Journal:  BMC Pharmacol Toxicol       Date:  2020-01-03       Impact factor: 2.483

6.  Serum exosomal microRNA-146a as a novel diagnostic biomarker for acute coronary syndrome.

Authors:  Long-Jun Li; Ya-Juan Gu; Lu-Qiao Wang; Wen Wan; Hua-Wei Wang; Xiao-Na Yang; Lin-Ling Ma; Li-Hong Yang; Zhao-Hui Meng
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

7.  Impact of national valsartan recalls on Veterans' outcomes.

Authors:  Paige L Morizio; Sara R Britnell; Andreina A Ottman
Journal:  Ther Adv Drug Saf       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.